Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
about
A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine CandidatesDengue Fever: Causes, Complications, and Vaccine StrategiesGuiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccineIntroducing a dengue vaccine to Mexico: development of a system for evidence-based public policy recommendationsMouse models to study dengue virus immunology and pathogenesisLatest developments and future directions in dengue vaccinesRational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaquesRecombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in MosquitoesWest Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacyDerivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys.Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse ModelTwo Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus SerotypesAn adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypesVaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1High Genetic Stability of Dengue Virus Propagated in MRC-5 Cells as Compared to the Virus Propagated in Vero CellsEvaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeysEvaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization TestsFlaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in miceDengue vaccines: state of the art.Utility, limitations, and future of non-human primates for dengue research and vaccine developmentYellow fever: the recurring plague.Dengue vaccines: recent developments, ongoing challenges and current candidates.Tetracycline-inducible packaging cell line for production of flavivirus replicon particlesCD8+ T cells complement antibodies in protecting against yellow fever virus.Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.The contribution of non-human primate models to the development of human vaccinesA chimeric live attenuated vaccine against Japanese encephalitis.Dengue Virus Infection of Aedes aegypti Requires a Putative Cysteine Rich Venom Protein.Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin AmericaDengue vaccine: priorities and progress.Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysisTesting of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacyImmunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.Development and characterization of the replicon system of Japanese encephalitis live vaccine virus SA14-14-2.
P2860
Q24282617-CE8620D9-5D42-40E9-A788-32F6D76118B3Q26700082-376294A4-3BA4-4E0A-B156-15A775C5F070Q26782367-3A6D4684-C1EB-4B63-8684-20EBB7825DECQ26823330-C307865E-7705-4CF5-9775-A407A76DB9C2Q27010151-9C09AC0B-C246-4FD3-AC89-C1BD50FA10F7Q27023422-B9585220-1864-4ECE-9DB5-0FB0AC1BABAEQ27334248-932B2C6D-58C2-4AB1-84ED-F675875290F2Q27469314-74546DCB-D712-44F7-818C-D5202F589A23Q27469872-83AA727A-EFBB-406D-9C8E-7DC6B54FA6E9Q27469921-C492966B-F7BD-4681-942B-22B71ED21766Q27469932-E922ACAE-C350-422B-A8AD-DB44B9C15291Q27469955-817519B8-960B-45D9-B04B-69013CA252F0Q27471660-874088EF-EB1F-4DBA-A949-9557943E7A90Q27472847-7CCEAA07-692A-48F1-91CB-7205AB065C6EQ27473317-A9C12340-B572-4DE0-9C28-4B09785E5F80Q27478075-5BEA1C30-2016-4CA5-B3DD-227B26690C5EQ27478104-88717BF2-2EDB-4F1D-93BB-E295976A27B7Q27478162-464FAAA3-5EE3-4DBB-B1DC-D980559522B7Q27485473-1EBD513A-AD9A-44FF-BBD4-7C997077A70FQ27487013-81414218-14BE-4EB7-9E95-CE28CE1EB185Q27488878-7FF70C62-EFE7-4E78-8ED5-50FEC6AFFFB9Q30857727-94311B51-A9A2-42AF-8518-3BAC228322C8Q34066921-DF5B1433-203D-4922-8240-4C9BFEFC8B4AQ34109652-73CF5AC3-CEE0-4821-B68F-26544C0EFD01Q34238916-2DC9DCF4-6004-4E37-84EC-5389DFBDF6A4Q34359311-CBC55A07-EEF8-4E0D-AC19-FD175E8C67BCQ34367194-742C934E-EADD-4FA0-972B-643E3B676E1FQ34552578-CF0A1415-D903-496F-8586-2964F2FBF548Q34980404-D3BEDC2B-390F-422D-8A48-D5C9BD928CD7Q35246126-4581F2C0-F318-4854-953A-D2699863EC6CQ35737990-178F20EE-FE3A-42F9-A0E0-81AEEFCCDB78Q35791746-B0F608BA-F4EB-4A67-BFFD-58E7550BC07DQ35817119-2685E6DD-919E-411D-AB2C-8CFA080B5BEFQ35836631-E5C44305-8F56-4CFE-A8A0-86EDBAF07208Q35964754-5BBF9193-5289-4F18-9915-E0E35D07B799Q36082908-D56CCE74-1589-4614-A8AA-C6F699714A81Q36450864-95AA47A5-BED3-477E-A463-71FCA896D669Q36631286-8616469E-392F-4B15-AB52-64E5F1B9A198Q36667964-5F6CE98D-60F3-434C-821E-A4328A6AEA4EQ36718676-7E364A8E-D06C-4780-916E-9B1D7F293706
P2860
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@ast
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@en
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@nl
type
label
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@ast
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@en
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@nl
prefLabel
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@ast
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@en
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@nl
P2093
P2860
P3181
P1433
P1476
Recombinant chimeric yellow fe ...... rotective in nonhuman primates
@en
P2093
K Georgakopoulos
M Ratterree
T J Chambers
P2860
P304
P3181
P356
10.1128/JVI.74.12.5477-5485.2000
P577
2000-06-01T00:00:00Z